CALCUTIONS AREA
CLICK ON CALCULATOR
Infant Data
Results
MEDICAL INFORMATIONS
INDICATIONS
- Treatment of cholestasis: associated with parenteral nutrition, biliary atresia, and cystic fibrosis.
- Dissolve cholesterol gallstones.
- Cholestasis: During first course therapy ursodiol reduced direct bilirubin by 1.89 mg/d compared with an increase of 0.76 mg/dL (p = 0.03) for phenobarbital in a retrospective study of 68 preterm and term newborns with direct bilirubin greater than 3 mg/dL. The change for all treatment courses were -3.96 mg/dL for ursodiol and +0.28 mg/dL for phenobarbital. Median dosages were ursodiol 27.43 mg/kg/day enterally and phenobarbital 4.48 mg/kg/day IV.
CONTRAINDICATIONS/PRECAUTIONS
Contraindicated in patients with complete biliary obstruction.
ADVERSE EFFECTS
Nausea/vomiting, abdominal pain, constipation, and flatulence.
MONITORING
Hepatic transaminases and direct bilirubin concentration.